Abstract: Initial treatment for ovarian cancer responds well to surgery and chemotherapy drugs, but tumor recurrence or chemotherapy resistance often leads to treatment failure. Endocrine therapy offers new treatment options for patients with relapsed or drug-resistant ovarian cancer. Endocrine drugs have the advantages of less adverse reactions, good tolerance and low treatment cost. Compared with single drugs, combination of molecular targeted drugs, anti-angiogenic drugs and chemotherapy drugs may exert synergistic effects and drug sensitization to improve the effect of endocrine therapy. This article mainly reviewed the research progress of endocrine therapy in ovarian cancer, and provided theoretical basis for endocrine therapy in ovarian cancer.